InspireMD Postpones $40 Million Registered
Common Stock Offering, Citing Market
TEL AVIV Israel, Nov. 16 –
InspireMD, Inc. (“InspireMD” or the “Company”) announced that, based on recent adverse market conditions,
it has chosen to postpone its planned registered public offering of $40 million worth of its shares of common stock until a later
InspireMD’s registration statement
on Form S-1, as filed with the Securities and Exchange Commission, has not been withdrawn and the Company expects to continue to
evaluate the timing for the offering.
About InspireMD, Inc.
InspireMD is a medical device company focusing
on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue
applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the
OTC under the ticker symbol NSPR.
About MGuard™ Embolic Protection
MGuard™ EPS combines a coronary stent
merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin
polymer micron net that is integrated with the stent. The MGuard EPS is designed to provide outstanding and lifelong embolic protection,
without affecting deliverability. MGuard EPS is CE Mark approved. MGuard™ is not approved for sale in the U.S. by the U.S.
Food and Drug Administration at this time.
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks
and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi)
our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the
fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing
us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Transition Report on From 10-K/T and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future
events or otherwise.
For additional information: